© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Learning from the ups and downs of cancer treatment, especially watching loved ones deal with the havoc of side effects, it's easy to grasp why something like dexrazoxane hydrochloride matters. Anthracyclines like doxorubicin, while effective against many tumors, carry the risk of heart damage. That risk triggered researchers to dig for a solution. Dexrazoxane's roots stretch back to the 1970s, born out of efforts to blunt this damage without undermining the fight against cancer. It reached clinical relevance in the 1990s, gaining approval as a cardioprotective agent. Real people—kids and adults—got to continue life-prolonging chemo with a better shot at keeping their hearts strong because of this work.
Dexrazoxane hydrochloride presents itself as a white, odorless powder that dissolves in water and forms a slightly acidic solution. Unlike flashy colors or scents, it tells its story through stable, unassuming basics. Chemically, dexrazoxane carries a somewhat rare ring structure that lets it chelate iron. That detail anchors its role: cancer treatments like doxorubicin drive up free radicals in the heart by pulling in iron, tearing at heart muscle. Dexrazoxane steps in, binding iron, stopping the trouble before it starts. It comes with a solid shelf life and stands up through the rigors of clinical environments. That stability translates to predictability, which, for patients and healthcare workers, means trust.
The path from raw material to usable medicine doesn't happen by accident. The preparation calls for careful synthetic steps, stringing together molecules through piperazinedione intermediates and using controlled hydrolysis. Each technique has a role—ensuring purity, maintaining potency, and limiting unintended byproducts. Some labs tinker with the process, shaving off reaction time or filtering out impurities more cleanly, aiming for reliability batch after batch. Advances come from both academic circles and pharma industry push, as both groups lean into producing this compound at scale safely.
Dexrazoxane’s label spells out critical technical details: dosage, reconstitution, and storage. Healthcare workers rely on these specifics—what concentration to mix, what temperature keeps it stable, what warnings deserve full attention. It goes straight into vein, documenting the amount based on the chemotherapy dose. Given its role in pediatric cancers, every minor instruction on preparation and handling carries real weight. Proper documentation keeps errors low and safety high.
Safety and operations standards for chemoprotective agents like dexrazoxane lean on hard-learned lessons. Chemistry alone doesn’t protect—the right gloves, mixing in biological safety cabinets, thorough staff training, and strict record-keeping combine to shield both patients and staff. Studies on exposure risks in pharmacies helped shape these rules. New research considers how best to extend these protections and whether automation or closed systems could further limit occupational hazards.
Most people learn about dexrazoxane as a counter for anthracycline-induced cardiotoxicity, but its value stretches further. It also treats accidental anthracycline leakage into tissues, preventing necrosis. The iron-chelating core, which gave it purpose in heart protection, nudges researchers to wonder about uses in ischemia-reperfusion injury, radiation protection, and even rare metabolic diseases. Trials in pediatric settings continue to track not only heart health, but long-term growth and development, considering the lifelong impact for children surviving cancer.
No medicine travels without some risk. Dexrazoxane’s toxicity research explores double-edged territory. Some worry over bone marrow suppression, concerns raised in early animal studies. Years of clinical experience and ongoing registry data now offer a clearer map of these effects, giving prescribers the chance to balance risk and reward for each patient. The question of whether dexrazoxane affects anti-tumor efficacy surfaces periodically; most data show it does not harm overall survival, but continued vigilance through well-constructed trials remains essential.
In clinics and literature, dexrazoxane hydrochloride appears under a handful of names—ICRF-187, Zinecard, and sometimes Cardioxane. Those who spend long hours in pediatric oncology units or research labs know these names not just from journals but from daily experience, each representing efforts to bring options to tough conversations about risk and survivorship.
Current research doesn’t stop at reducing heart damage. Scientists chase a deeper understanding of how dexrazoxane’s protective effects work, not just in the heart, but across tissues taxed by oxidative stress. Teams tinker with new analogs, sharper dosing strategies, and complementary approaches that block toxicity without opening the door to new risks. Community hospitals and academic centers share data, looking for trends and spotting safety signals. New work in pharmacogenomics may one day match dexrazoxane use with patient genetics for personalized protection, maximizing benefits and shrinking harms.
More kids and adults walk away from cancer than ever before. More families sit together for years beyond an initial diagnosis, thanks to better drugs and sharper care. But the shadow of treatment-induced illness lingers. Medicines like dexrazoxane stand as proof that progress means looking at the whole person, not just the tumor. Every safe step forward rests on careful chemistry, relentless follow-up, and a willingness to take honest stock of risks. The people whose futures depend on these decisions count on continued commitment in research and clinical practice—not just to innovate, but to do so with both skill and heart.
Chemotherapy does its job, but it's rough on the body. Growing up, I saw a close family friend go through cancer treatments that brought as much fear about the drugs as the disease itself. Those infusions save lives, yet powerful medicines like anthracyclines, especially doxorubicin, can cause lasting heart problems that often sneak up long after treatment ends. That possibility leaves both doctors and patients searching for options that allow cancer care without trading away heart health.
Dexrazoxane hydrochloride offers a layer of protection that’s not just another pill to swallow. Its role stands out because it doesn’t treat cancer. Instead, it works to defend the heart from the damage anthracycline chemotherapy can unleash. It interrupts the chemical reaction that releases free radical particles—a process at the heart of chemotherapy-induced heart injury. In plain terms, dexrazoxane steps in as a shield, especially for those who have to face multiple rounds of aggressive drugs or who already have risks tied to their heart.
Researchers have looked closely at dexrazoxane for years. Multiple studies point out a serious drop in heart complications for patients—both children and adults—who receive it alongside their cancer drugs. The drug’s safety came under scrutiny over the years, mostly due to early concerns about possible impacts on cancer outcomes or risk of infections. Large clinical trials have not found evidence that dexrazoxane reduces the chance of cancer treatment working or raises the risk of new cancers in people who receive it. That reassurance matters because treatment-resistant cancers and persistent side effects can derail recovery.
Doctors do not prescribe dexrazoxane for everyone getting chemotherapy. Decision-making takes real conversations between patients, families, and oncologists. Factors include age, how many anthracycline doses someone has had, and individual risk profile for heart problems. The FDA has approved dexrazoxane for adults and children who reach a certain cumulative level of anthracycline exposure, but physicians sometimes turn to it earlier, especially for patients who already carry high risk for cardiac events. As a parent, I’d want to understand these discussions if my child ever ended up in the cancer ward.
Access and awareness still challenge patients. Hospitals need to make sure dexrazoxane is available and affordable, because its brand and generic forms both cost money. Insurance company coverage varies, and not all institutions prioritize cardiac protection. Oncologists take on huge responsibility—navigating the fine line between fighting cancer and minimizing harm. Training, up-to-date guidelines, and patient advocacy all offer help here. As people living longer after cancer, we need to push for smarter ways to block late-onset side effects like heart failure.
Chemotherapy saves lives. Cancer patients deserve every tool to keep living their own. Dexrazoxane hydrochloride—and drugs like it—prove we can improve the whole journey, not just the outcome. Everyone involved needs transparency and honesty from their healthcare team about choices, risks, and protective steps available. As medicine advances, demand better protection—not just aggressive attack—from cancer treatment.
Dexrazoxane hydrochloride brings hope to people facing chemotherapy. It’s designed to protect the heart from the harmful effects of some cancer drugs, particularly those in the anthracycline group like doxorubicin. The benefits are real—less risk of long-term heart damage means one less thing to worry about during and after cancer treatment. Still, every good treatment comes with its own set of challenges.
Most patients don’t walk away from the infusion chair without noticing some changes. The most well-known side effect is bone marrow suppression. This means dexrazoxane can make it harder for the body to produce enough white blood cells, red blood cells, and platelets. A drop in these numbers often leaves people feeling more tired than usual, more likely to catch infections, and bruising or bleeding may show up more easily. Personal experience tells me that the fatigue isn’t just about feeling sleepy—it’s the kind that makes even simple grocery runs feel monumental.
Nausea and vomiting show up in many stories shared in waiting rooms and support groups. Even though medications can control these symptoms, they tend to bother folks for a few days after each dose. As a nurse, I’ve seen people bring ginger candies and take deep breaths before treatments, hoping to keep the worst of it at bay.
Alopecia, or hair loss, is less common than with the actual chemotherapy drugs, but it does appear for some. Many patients have told me the emotional stress of hair loss sometimes outweighs the physical toll, especially during long stretches of treatment.
Dexrazoxane sometimes causes pain or redness at the injection site. The area can feel hot, swollen, or tender for a few hours. It’s not severe for most, but a few need ice packs and extra care. Occasionally, skin rash and mild itching develop after treatment. Hydration and using gentle skin lotions seem to help.
Temporary increases in certain liver enzymes happen. Blood work during therapy tells the story. Most people don’t notice anything in their daily routine, but those with liver conditions need careful monitoring. Small changes in kidney function also crop up during treatment, though they are less common.
Rarely, patients report dizziness or shortness of breath. The drug can lower blood pressure briefly right after infusion. Patients usually recover quickly, but it’s wise for medical teams to keep a close eye in the infusion clinic, especially early on.
The best approach involves taking blood counts before every treatment. Nurses watch for warning signs—fevers, nosebleeds, or breathlessness mean action. Nausea medications, extra fluids, and plenty of communication help even out the rough spots. Support groups and talking with social workers go a long way toward managing the emotional side of side effects, especially hair changes or fatigue that don’t fade quickly.
Talking honestly with healthcare providers about symptoms brings better care. Too many patients hide fatigue or infections because they don’t want to worry loved ones. Truthful reporting lets doctors adjust dosages or add supportive medicines. Balancing protection and comfort turns into a team effort, where each person brings experience and questions to the table.
Anyone who’s ever spent time around cancer treatment knows the challenges aren’t limited to just the disease—side effects of therapy can sometimes be overwhelming. Dexrazoxane hydrochloride steps in during certain chemotherapy regimens, particularly with doxorubicin, to shield the heart from damage. The way it’s given isn’t left to chance. Nurses and oncologists keep it controlled, reliable, and as easy as possible under the circumstances.
The drug is injected directly into a vein. It isn’t taken by mouth or rubbed on the skin. Sticking with intravenous administration means it gets to work fast, letting doctors tweak the dose if conditions change. Patients have already gone through enough—nobody wants to add more pills or uncertainty to the process on treatment days.
Timing makes a big difference. Dexrazoxane must be given just before, or at the same time as, the chemotherapy agent that can harm the heart. Skipping or delaying isn’t an option. The infusion goes in over a specific timeframe—around 15 minutes, so it lines up smoothly with a chemotherapy session. If someone asks why doctors stick to these rules so carefully, the reason boils down to both protection and safety.
Doses get calculated based on how much chemotherapy a person is getting, as well as their individual size and health profile. Straying from the recommended amount puts the patient at risk of losing the benefit, or picking up side effects of its own. Using a set protocol helps experienced nurses spot problems early and take action before things go sideways.
From what I’ve observed in the clinic, patients often find IV administrations easier to manage than juggling pills, especially when already feeling drained. The setup does require an IV line, and that can mean a brief pinch, though seasoned oncology nurses know how to find a good vein without making it a hassle. Some folks worry about more infusions, but most agree it's better to spend some extra time at the clinic if it keeps the heart beating strong enough to finish chemotherapy.
Real concerns come up during these treatments—questions about extra side effects, potential for allergic reactions, or whether the medicine interacts with other drugs. Transparency answers most fears. The FDA has laid down clear guidance, pointing out how it can cause issues like low blood counts or even local irritation if the drug leaks outside the vein. Clinics stay ready: quick action, ice packs, antidotes if needed. Cancer care always comes with tough choices, but patients appreciate knowing every safeguard is in place.
Health staff keep looking for ways to make treatment days less stressful and safer. Some centers have started using smaller, more comfortable IV catheters, or warm compresses to make veins easier to find. Others push for even more patient education, handing out booklets and offering open question times, so patients walk in confident and aware.
Cancer’s hard enough—having a therapy option like dexrazoxane that shields the heart lets more people finish their full course of treatment. This isn’t just about adding extra medicine. It’s about giving patients a real shot at better outcomes with fewer lasting scars.
Dexrazoxane hydrochloride shows up often in cancer care, mostly for people getting certain kinds of chemotherapy. Hospitals use it to help protect the heart from the damage that can come with some cancer drugs, especially doxorubicin. For many facing these treatments, dexrazoxane gives a little extra hope when heart risks are part of the conversation. Still, this isn’t a medication meant for everyone. It comes with serious guidelines meant to keep patients out of trouble and avoid more harm than help.
Pediatric use sparks some of the most heated debates around this drug. The FDA does not approve dexrazoxane for children receiving doxorubicin unless clear heart damage risks swing the balance. Data from the Children’s Oncology Group has linked dexrazoxane in young patients with a higher chance of getting second cancers, especially acute myeloid leukemia. Parents and doctors face a tough choice here; short-term heart protection can turn into long-term danger. Families should talk openly with their cancer care teams and weigh every factor before including this drug in a treatment plan for a child.
Mothers-to-be shouldn’t touch dexrazoxane unless the situation turns desperate. Animal studies have shown birth defects. There’s not enough research in pregnant women, but the risk looks real enough. Doctors often listen to the warning signs—if a safer path exists, they take it. New mothers risk passing the drug to their babies through breast milk. For many, avoiding this medicine during pregnancy or nursing offers better peace of mind.
Some bodies react fast and violently to the ingredients in dexrazoxane. Patients with a history of allergic reactions to this or related drugs stand on shaky ground. Allergic shock can turn a tough situation deadly in minutes. That risk overshadows any potential benefit. In my experience, allergy stories travel fast through hospital corridors, which helps teams stay sharp about patient safety and medical histories.
This drug clears from the body through the liver and kidneys. If either organ struggles, dexrazoxane builds up to unsafe levels. Dose changes sometimes help, but doctors often hold off entirely if patients show serious liver or kidney disease. I’ve seen mistakes happen—missing early signs of liver or kidney trouble turns simple support care into a medical storm. Honest conversations about past health problems help prevent disaster.
Medical guidelines discourage dexrazoxane early in chemotherapy. Studies suggest the drug can possibly weaken the cancer-killing power of doxorubicin during the first rounds of treatment. Most experts hold off on dexrazoxane until later rounds, only introducing it once cumulative heart risks start to add up. This careful timing reflects both experience and evolving data from clinical research.
Dexrazoxane hydrochloride should never come from a place of guesswork. Only patients facing real heart risks from specific chemotherapy drugs get the green light. Each case gets a custom approach. Any shortcuts or secondhand advice can backfire. Better results always follow strong teamwork among patients, oncologists, nurses, and pharmacists.
Newer chemotherapy plans and dosing strategies sometimes offer similar heart protection without needing extra medication. People already managing allergies, organ problems, or family plans deserve honest updates from their oncology teams. Most who face tough odds appreciate plain talk over high-minded theories. In my years around cancer care, trust and direct conversation protect people far more reliably than any bottle on the pharmacy shelf.
Anyone locked in a battle with cancer knows just how much the treatment process pushes the body’s limits. Dexrazoxane Hydrochloride steps in as a kind of shield, standing between the heart and the tough damage that can come with certain chemotherapy drugs. But even a guard needs to keep an eye on what’s coming from the sidelines. Mixing drugs isn’t like mixing colors; sometimes the outcome surprises everyone, and not in a good way.
Dexrazoxane Hydrochloride came around because anthracycline chemotherapy, like doxorubicin, hits cancer cells hard but can also leave the heart struggling to keep up. Dexrazoxane helps by interrupting some of the chemical processes that lead to that heart damage. Researchers poured a lot of time and energy into getting this right, because chemotherapy patients tend to need a lot of different medications. Some drugs become like background noise; others draw attention. Dexrazoxane draws attention.
It’s no secret that cancer patients often juggle plenty of medications: antibiotics, anti-nausea pills, pain relievers, blood thinners, and more. Some reports point out risks when Dexrazoxane meets certain drugs. For example, using Dexrazoxane at the same time as live vaccines (like those for mumps or measles) doesn’t end well, since the immune system is running at low power during chemotherapy. Infections hit harder and last longer. Mixing with blood thinners—warfarin, for example—means doctors need to watch for odd bleeding or clotting patterns, because both drugs put pressure on the body’s clotting mechanisms.
Several cancer centers keep close track of liver and kidney function in patients on Dexrazoxane, not just because of potential side effects, but because other drugs can raise the load on these organs. Drugs broken down by the same pathways, such as certain antibiotics or antifungals, can lead to drug build-up and toxicity. In fact, a study published in The Annals of Pharmacotherapy found that antibiotics like ciprofloxacin and antifungals like itraconazole may compete with Dexrazoxane for metabolic space, leading to stronger or longer-lasting effects of one or both medications.
Ten years on a hospital pharmacy team showed me just how much confusion swirls around new medicines. One day, I worked with a patient trying Dexrazoxane for the first time. Family members had packed over-the-counter cold pills, sleeping aids, and herbal teas—regular at-home comforts. Some of these so-called harmless products can get in the way, because supplement manufacturers rarely study drug interactions. Most doctors keep an open line with their pharmacists, combing through full medication lists at every visit. This cross-checking looks simple but saves lives, especially with drugs that, like Dexrazoxane, change how other medicines act in the body.
No one expects patients to memorize medical textbooks. But real power sits in questions. Any time a new drug enters the routine, patients can ask about possible interactions. Technology lends a hand: large hospitals use advanced electronic medical records to flag risk combinations. Community pharmacies step in to catch mistakes, double-checking for overlooked supplements and OTC products. Better education for patients, clear labels, and frequent medication reviews close the gap even further.
Navigating cancer is hard enough without added complications from unexpected drug interactions. Dexrazoxane Hydrochloride may protect the heart, but it comes with its own set of traffic rules in the crowded journey through cancer treatment. Working with informed health professionals, keeping an updated medication list, and speaking up about even “minor” products keeps patients safer and their road to recovery clearer.
| Names | |
| Preferred IUPAC name | 2-[(3,5-Dioxopiperazin-1-yl)methyl]-2,4,6,8-tetraazabicyclo[3.3.1]nonane-3,7-dione;hydrochloride |
| Other names |
Cardioxane ICRF-187 ADR-529 Zinecard Totect |
| Pronunciation | /ˌdɛk.srəˈzɒk.seɪn haɪˌdrɒk.səˈlaɪd/ |
| Identifiers | |
| CAS Number | 24584-09-6 |
| 3D model (JSmol) | Here is the '3D model (JSmol)' string for **Dexrazoxane Hydrochloride**: ``` dexrazoxane_hydrochloride.mol ``` If you need the detailed molecular structure file content (as a string, such as an actual MOL or SDF format), please let me know! |
| Beilstein Reference | 2109083 |
| ChEBI | CHEBI:7632 |
| ChEMBL | CHEMBL1201299 |
| ChemSpider | 107425 |
| DrugBank | DB01176 |
| ECHA InfoCard | 03b21f76-096a-4f82-8e7b-29cecac25526 |
| EC Number | 68439-29-6 |
| Gmelin Reference | 82849 |
| KEGG | D00552 |
| MeSH | D016601 |
| PubChem CID | 6918499 |
| RTECS number | MB9476000 |
| UNII | 7BVB9C41DQ |
| UN number | UN3241 |
| Properties | |
| Chemical formula | C11H16N4O4·HCl |
| Molar mass | 329.76 g/mol |
| Appearance | White to off-white crystalline powder |
| Odor | Odorless |
| Density | 1.018 g/cm3 |
| Solubility in water | Very soluble in water |
| log P | -2.6 |
| Acidity (pKa) | 7.6 |
| Basicity (pKb) | pKb: 2.7 |
| Magnetic susceptibility (χ) | -51.5e-6 cm³/mol |
| Dipole moment | 2.3 ± 0.6 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 262.2 J⋅mol⁻¹⋅K⁻¹ |
| Pharmacology | |
| ATC code | V03AF02 |
| Hazards | |
| Main hazards | May cause cancer; causes damage to organs; harmful if swallowed; may cause genetic defects. |
| GHS labelling | GHS02, GHS07, GHS08 |
| Pictograms | GHS05, GHS07 |
| Signal word | Warning |
| Hazard statements | Hazard statements: "H302: Harmful if swallowed. H312: Harmful in contact with skin. H332: Harmful if inhaled. H351: Suspected of causing cancer. |
| Precautionary statements | P201, P202, P260, P264, P270, P280, P308+P313, P405, P501 |
| NFPA 704 (fire diamond) | 2-1-1 |
| Lethal dose or concentration | LD50 (oral, rat): 3500 mg/kg |
| LD50 (median dose) | LD50 (median dose): Mouse (IV) 572 mg/kg |
| NIOSH | Not Listed |
| PEL (Permissible) | Not established |
| REL (Recommended) | 500 mg |
| IDLH (Immediate danger) | The IDLH (Immediate danger) for Dexrazoxane Hydrochloride is **"Not listed"**. |
| Related compounds | |
| Related compounds |
EDTA ICRF-193 ICRF-154 ICRF-187 Doxorubicin |
